SYNEBIO
Financiado
High-throughput combinatory drugs testing on in vitro 3D cells model platform
Drug combinations can lead to the discovery of novel drugs by increasing efficacy or lowering toxicity through synergy. This can boost existing drugs, rescue drug candidates, and accelerate drug discovery for yet poorly addressed...
Drug combinations can lead to the discovery of novel drugs by increasing efficacy or lowering toxicity through synergy. This can boost existing drugs, rescue drug candidates, and accelerate drug discovery for yet poorly addressed diseases. However, predicting synergy is difficult, and finding synergies requires high-throughput screening (HTS) in advanced cell models. Current solutions propose either HTS in 2D cell cultures or low throughput assays in 3D cell cultures, but not both.
On the basis of a technology developed in the ERC-funded AbioEvo project, we devised an innovative microfluidic platform for 3D culture and HTS of drug combinations. Miniaturization densifies routine 3D assays, resulting in a throughput increase of 10 to 100 times. Fluidic automation reduces liquid handling 500 times for a 100x100 drug library at a 10-point dose-response combinatorial screening. Furthermore, 3D culture models better predict later physiological responses, thus increasing the success probability of downstream drug development stages. We have shown dose-response measurements of 144 antibiotic combinations on bacteria on a single chip.
In this POC, we aim to demonstrate the applicability of our technology to human cells and benchmark it based on existing screens for breast cancer cells. We will adapt the cell culture conditions and data analysis, perform market analysis, and examine industrialization feasibility. This will put us in a position to create a spin-off to reach the preclinical drug screening market and identify the most promising therapeutic areas. Indeed, the technology has the potential to screen for synergistic drug combinations at an earlier stage of the drug discovery process (thanks to miniaturization and automation) while providing a more reliable cellular response for later stages (thanks to 3D culture).
ver más
Duración del proyecto: 20 meses
Fecha Inicio: 2022-10-07
Fecha Fin: 2024-06-30
Fecha Fin: 2024-06-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-POC2:
ERC PROOF OF CONCEPT GRANTS2
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDU...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5